West Pharmaceutical Services, Inc. (WST) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
WST Revenue Growth
Revenue Breakdown (FY 2025)
WST's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
WST Revenue Analysis (2014–2025)
As of May 6, 2026, West Pharmaceutical Services, Inc. (WST) generated trailing twelve-month (TTM) revenue of $3.22 billion, reflecting exceptional growth of +21.0% year-over-year. The most recent quarter (Q1 2026) recorded $844.9 million in revenue, up 5.0% sequentially.
Looking at the longer-term picture, WST's 5-year compound annual growth rate (CAGR) stands at +7.4%, indicating steady revenue expansion. The company achieved its highest annual revenue of $3.07 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows WST's business is primarily driven by Proprietary Products (81%), and Contract Manufactured Products (19%). With over half of revenue concentrated in Proprietary Products, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ATR (+8.9% YoY), GTLS (+2.5% YoY), and AVTR (-2.0% YoY), WST has underperformed the peer group in terms of revenue growth. Compare WST vs ATR →
WST Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| WSTCurrent | $3.2B | +21.0% | +7.4% | 20.1% | |
 ATR | $3.8B | +8.9% | +5.2% | 13.6% | |
 GTLS | $4.3B | +2.5% | +29.4% | 15.2% | |
 AVTR | $6.6B | -2.0% | +0.5% | -3.8% | |
 AMCR | $15.0B | +64.8% | +3.8% | 6.7% | |
 SEE | $5.4B | -0.6% | +1.8% | 13.5% |
WST Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.07B | +6.3% | $1.10B | 35.9% | $617.4M | 20.1% |
| 2024 | $2.89B | -2.0% | $1.00B | 34.6% | $594.6M | 20.6% |
| 2023 | $2.95B | +2.3% | $1.13B | 38.4% | $710.9M | 24.1% |
| 2022 | $2.89B | +1.9% | $1.14B | 39.5% | $763.5M | 26.5% |
| 2021 | $2.83B | +31.9% | $1.17B | 41.5% | $758.7M | 26.8% |
| 2020 | $2.15B | +16.4% | $767.9M | 35.8% | $419.0M | 19.5% |
| 2019 | $1.84B | +7.3% | $608.8M | 33.0% | $297.2M | 16.1% |
| 2018 | $1.72B | +7.4% | $546.3M | 31.8% | $254.8M | 14.8% |
| 2017 | $1.60B | +6.0% | $514.8M | 32.2% | $229.7M | 14.4% |
| 2016 | $1.51B | +7.9% | $501.0M | 33.2% | $215.5M | 14.3% |
Full WST Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See WST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs WST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare WST vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonWST — Frequently Asked Questions
Quick answers to the most common questions about buying WST stock.
Is WST's revenue growth accelerating or slowing?
WST revenue is accelerating at +21.0% year-over-year, exceeding the 5-year CAGR of +7.4%. TTM revenue reached $3.2B. Growth momentum has increased versus prior periods.
What is WST's long-term revenue growth rate?
West Pharmaceutical Services, Inc.'s 5-year revenue CAGR of +7.4% reflects the sustained expansion pattern. Current YoY growth of +21.0% is above this long-term average.
How is WST's revenue distributed by segment?
WST reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.